Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10457102 | 0.96 | — | — | |
| SCHEMBL10935107 | 0.93 | EPHX1 (0.38) | EPHX1HIF1A | |
| SCHEMBL9351268 | 0.89 | — | — | |
| SCHEMBL10457201 | 0.89 | — | — | |
| SCHEMBL8449083 | 0.89 | APLNR (0.32) | — | |
| SCHEMBL7345447 | 0.86 | EPHX1 (0.45) | EPHX1HIF1A | |
| SCHEMBL15829236 | 0.86 | EPHX1 (0.45) | EPHX1HIF1A | |
| SCHEMBL16007530 | 0.86 | EPHX1 (0.45) | EPHX1HIF1A | |
| SCHEMBL11111508 | 0.86 | EPHX1 (0.45) | EPHX1HIF1A | |
| SCHEMBL6676683 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2391211-A1 | METHODS AND COMPOSITIONS FOR TREATING BREAST CANCER | Genzyme Corporation (US) | 2011-12-07 | — | — | EP | claimed |
| US-20110280827-A1 | METHODS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL MALIGNANCIES | HU YANPING (US) | 2011-11-17 | — | — | US | claimed |
| US-20110281814-A1 | METHODS AND COMPOSITIONS FOR TREATING BREAST CANCER | GENZYME CORPORATION | 2011-11-17 | — | — | US | claimed |
| EP-2384115-A1 | METHODS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL MALIGNANCIES | Genzyme Corporation (US) | 2011-11-09 | — | — | EP | claimed |
| US-20110245265-A1 | CXCR4 ANTAGONISTS FOR KIDNEY INJURY | GENZYME CORPORATION (US) | 2011-10-06 | — | — | US | claimed |
| WO-2010088398-A1 | METHODS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL MALIGNANCIES | GENZYME CORPORATION (US) | 2010-08-05 | — | — | WO | claimed |
| WO-2010088401-A1 | METHODS AND COMPOSITIONS FOR TREATING BREAST CANCER | GENZYME CORPORATION (US) | 2010-08-05 | — | — | WO | claimed |
| US-20090221683-A1 | Combination of CXCR4 Antagonist and Morphogen to Increase Angiogenesis | CARITAS ST.ELIZABETH MEDICAL CENTER OF BOSTON, INC (US) | 2009-09-03 | — | — | US | claimed |
| US-20080063624-A1 | METHODS TO MOBILIZE PROGENITOR/STEM CELLS | GENZYME CORPORATION | 2008-03-13 | — | — | US | claimed |
| US-20060223180-A1 | Methods to mobilize progenitor/stem cells | ANORMED INC. | 2006-10-05 | — | — | US | claimed |
| US-20060193826-A1 | Methods to mobilize progenitor/stem cells | ANORMED INC. (CA) | 2006-08-31 | — | — | US | claimed |
| US-6987102-B2 | Methods to mobilize progenitor/stem cells | ANORMED, INC. (CA) | 2006-01-17 | — | — | US | claimed |
| WO-2005002522-A2 | COMPOSITIONS AND METHODS FOR TREATING TISSUE ISCHEMIA | CARITAS ST. ELIZABETH'S MEDICAL CENTER OF BOSTON, INC. (US) | 2005-01-13 | — | — | WO | claimed |
| EP-1148875-B1 | METHODS AND COMPOSITIONS TO ENHANCE WHITE BLOOD CELL COUNT | ANORMED INC (CA) | 2004-06-09 | — | — | EP | claimed |
| US-6670354-B2 | Administering cyclic polyamine compound to elevate white blood cell (WBC) count | ANORMED, INC. | 2003-12-30 | — | — | US | claimed |
| US-20030130250-A1 | Methods to mobilize progenitor/stem cells | ANORMED, INC. (CA) | 2003-07-10 | — | — | US | claimed |
| US-20020058653-A1 | Methods to enhance white blood cell count | ANORMED, INC. (CA) | 2002-05-16 | — | — | US | claimed |
| US-6365583-B1 | ADMINISTERING NITROGEN CONTAINING CYCLIC COMPOUNDS FOR THERAPY OF ENHANCING WHITE BLOOD CELL COUNT | ANORMED, INC. | 2002-04-02 | — | — | US | claimed |
| EP-1148875-A1 | METHODS AND COMPOSITIONS TO ENHANCE WHITE BLOOD CELL COUNT | ANORMED INC. (CA) | 2001-10-31 | — | — | EP | claimed |
| WO-2000045814-A1 | METHODS AND COMPOSITIONS TO ENHANCE WHITE BLOOD CELL COUNT | ANORMED INC. (CA) | 2000-08-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245265-A1 | CXCR4 ANTAGONISTS FOR KIDNEY INJURY | CXCR4, CXCR3, CXCR1 | EPHX1 1035/4885HIF1A 443/4885 |
| US-20080063624-A1 | METHODS TO MOBILIZE PROGENITOR/STEM CELLS | CXCR4, CXCL12, CCR2 | EPHX1 1660/4885HIF1A 574/4885 |
| US-20060193826-A1 | Methods to mobilize progenitor/stem cells | CXCR4, CCR2, CXCL12 | EPHX1 1684/4885HIF1A 568/4885 |
| US-20060223180-A1 | Methods to mobilize progenitor/stem cells | CXCR4, CXCL12, CCR2 | EPHX1 1648/4885HIF1A 534/4885 |
| US-20030130250-A1 | Methods to mobilize progenitor/stem cells | CXCR4, CXCL12, CXCR2 | EPHX1 1582/4885HIF1A 739/4885 |
| US-20090221683-A1 | Combination of CXCR4 Antagonist and Morphogen to Increase Angiogenesis | CXCL12, CXCR4, SDF4 | EPHX1 1105/4885HIF1A 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.